Jia Y, Liu LL, Su JL, Meng XH, Wang WX, Tian C. Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury. World J Clin Cases 2021; 9(6): 1284-1292 [PMID: 33644195 DOI: 10.12998/wjcc.v9.i6.1284]
Corresponding Author of This Article
Cui Tian, MHSc, Attending Doctor, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Taishan District, Tai'an 271000, Shandong Province, China. 15621589099@163.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2021; 9(6): 1284-1292 Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1284
Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury
Yan Jia, Li-Li Liu, Ji-Liang Su, Xiao-Hua Meng, Wei-Xin Wang, Cui Tian
Yan Jia, Li-Li Liu, Ji-Liang Su, Xiao-Hua Meng, Department of Critical Care Medicine, Shandong Taishan Hospital, Tai'an 271000, Shandong Province, China
Wei-Xin Wang, Cui Tian, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China
Author contributions: Jia Y and Tian C performed the operation; Liu LL and Wang WX designed this retrospective study; Su JL and Meng XH wrote the paper; Tian C was responsible for sorting the data.
Institutional review board statement: The study was reviewed and approved by the Research Ethical Committee of Shandong Taishan Hospital Institutional Review Board, No. 2017BL-045-01.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cui Tian, MHSc, Attending Doctor, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Taishan District, Tai'an 271000, Shandong Province, China. 15621589099@163.com
Received: November 3, 2020 Peer-review started: November 3, 2020 First decision: November 20, 2020 Revised: December 2, 2020 Accepted: December 16, 2020 Article in press: December 16, 2020 Published online: February 26, 2021 Processing time: 95 Days and 10.4 Hours
ARTICLE HIGHLIGHTS
Research background
Acute kidney injury is a serious disease.
Research motivation
To explore new methods for the treatment of acute kidney injury.
Research objectives
To examine the effect of alprostadil on continuous venous-venous hemofiltration (CVVH) in patients with acute renal injury (AKI).
Research methods
This was a retrospective study of 100 intensive care unit patients with AKI.
Research results
The clinical effect in the alprostadil group was better than that in the control group (P < 0.05); The urine output of patients in the alprostadil group returned to normal (9.1 ± 2.0 d) quicker than in the control group (10.6 ± 2.5 d), the difference was statistically significant (P < 0.05); adverse reactions occurred in the alprostadil group compared with the control group, but the difference was not statistically significant (P > 0.05).
Research conclusions
Alprostadil combined with CVVH in the treatment of severely ill patients complicated with AKI can effectively improve renal resistance index, partial pressure of oxygen in urine, and has a positive effect on improving renal function.
Research perspectives
New treatment methods are required for patients with acute kidney injury.
